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Background: The previous studies indicated that CrmA could ameliorate the interleukin-1β induced osteoarthritis.
In this study, we investigated the controlled-released cytokine response modifier A (CrmA) from hyaluronic acid
(HA)-chitosan (CS) microspheres to improve interleukin-1β (IL-1β)-stimulated dedifferentiation of chondrocytes.
Methods: A rat model of osteoarthritis (OA) in vitro was established using 10 ng/ml IL-1β as modulating and chondrocytes
inducing agent. HA-CS-CrmA microspheres were added to the medium after IL-1β was co-cultured with freshly isolated rat
chondrocytes for 48 hours. The chondrocytes viability and glycosaminoglycan (GAG) content were determined. The level of
CrmA secreted was detected by Enzyme-Linked Immunosorbent Assay (ELISA). The protein levels of type II collagen,
aggrecan, collagen I and IL-1β were detected using western blotting analyses.
Results: The CrmA release kinetics were characterized by an initial burst release, which was reduced to a linear
release over ten days. The production of GAG and the expression of type II collagen, aggrecan significantly
increased compared with the control group, while the expression of collagen I and IL-1β decreased.
Conclusions: This study demonstrated that HA-CS microspheres containing CrmA could attenuate the degeneration
of articular cartilage by maintaining the phenotype of chondrocytes during culture expansion. The suppression of
inflammatory cytokines activity within the joint might be one important mechanism of the action of the microspheres
in the treatment of OA.
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Osteoarthritis (OA) is the most prevalent disease of ar-
ticular joints. Pathophysiologic changes occur in OA
cartilage due to the excessive expression of cartilage
degrading proteinases, the resultant progressive break-
down of collagen fibers, and the degradation of proteo-
glycan, mainly aggrecan [1]. IL-1β is considered to play
an important role in the pathogenesis of OA, mainly
because it can induce the resorption of proteoglycan
and type II collagen [2,3]. Consequently, the inhibition* Correspondence: ma_bella@163.com; zhoupanghu@126.com
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unless otherwise stated.of the IL-1β pathway presents a promising means of pre-
venting cartilage degradation during OA pathogenesis. One
of the major endogenous inhibitors of the IL-1 pathway is
CrmA. CrmA can bond with IL-1β converting enzyme
(ICE) (caspase-1) as a pseudosubstrate. This serpin can pre-
vent the proteolytic activation of interleukin-1β, then block
the cleavage of pro-IL-1β by ICE thereby suppressing an
interleukin-1β response to infection and decreasing the
secretion of IL-1β [4,5].
Chitosan (CS), a partially deacetylated derivative from chi-
tin composed of D-gucosamine and N-acetylglucosamine, is
structurally similar to GAGs. CS is widely used to elaborate
different nanocarriers attributed to the capacity of the poly-
mer to interact with the negatively charged cell surfaces [6].
Many studies have shown its applications in drug, DNAs is an Open Access article distributed under the terms of the Creative
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biocompatibility and biodegradability [7-10].
Hyaluronic acid (HA) is another biocompatible anionic
biopolymer used in a wide array of clinical application.
HA is an abundant non-sulfated glycosaminoglycan com-
ponent of synovial fluid and extracellular matrices and
plays an important role in its function. It is involved in cell
adhesion, morphogenesis, and inflammation regulation
[11]. In osteoarthritis, intra-articular injection of HA can
improve the viscoelasticity of synovial fluid, augment the
flow of joint fluid, normalize endogenous hyaluronate syn-
thesis, inhibit hyaluronate degradation, reduce joint pain,
and improve joint function [12-14]. In our previous study,
our results have shown that HA could suppress chon-
drocyte apoptosis in IL-1β-induced osteoarthritis model
in a dose-dependent way [15]. Both of these can be con-
sidered as attractive materials for new biocompatible and
biodegradable polymers.
In this study, we attempted to combine the virtues of CS
and HA in the development of CrmA-loaded microspheres,
and intended for attenuate the degeneration of articular
cartilage. The interaction between these microspheres and
chondrocytes will be investigated, and their potential for
preventing OA chondrocytes dedifferentiation evaluated.
Methods
Materials
Chitosan (molecular weight:150 kDa, deacetylation:98%),
Hyaluronic acid (molecular weight:500-730 kDa), sodium
tripolyphosphate (STPP), and IL-1β ELISA kit were pro-
vided by Sigma-Aldrich. Cytokine response modifier A
(CrmA) was purchaseded from PeproTech. Trypsinase,
type II collagenase, DMEM/F12 Medium were purchased
from Gibco. All the other chemicals used were of the
highest available commercially grade.
Microsphere preparation and characterization
2 g of chitosan was dispersed into the acetic acid
(100 mL) under vigorous stirring for 3 h at ambient
temperature (below 20°C) to obtain a transparent chito-
san solution (2% w/v), and the hyaluronic acid solution
(0.1%, w/v) was obtained using the same method. Then,
a desired amount of chitosan solution (10 ml) and
hyaluronic acid fluid (5 ml) were immediately dispersed
with vigorous stirring to obtain a stable mixture of HA-CS
solution. A well-mixed suspension containing 100 mL of
paraffin oils and 1 g of Span 80 was dispersed in a reactor
and and stirred at 1000rmp for 1 h. 6 mL of HA-CS
solution prepared was dropped into the suspension
with a speed of 1 ml/min. The suspension in the vessel
was stirred at the same speed and temperature for an
additional 2 h. Next, 10 ml sTPP solution (10% w/v)
was added and kept for an additional 1 h at the same
stirring speed. After removing the supernatant liquidparaffin, HA-CS microspheres deposited in the bottom
were collected. The microspheres were washed with al-
cohol and acetone several times to completely remove
the residual paraffin oil and Span 80. Microspheres of
CS-CrmA, HA-CS-CrmA were prepared. Finally, the
microspheres were freeze-dried. The sizes and shapes
of the microspheres were examined under a scanning
electron microscope (SEM).
In vitro release profiles
Approximately 20 mg of microspheres, containing CrmA,
was dispersed into a phosphate-buffered saline (PBS,
PH = 7.4) solution containing 104 U/ml of lysozyme.
Next, this solution was placed in a shaking water bath
at 37°C at 135 rpm for various time periods, up to ten days.
Periodically, the microsphere suspension was centrifuged to
collect the supernatant for analysis, followed by the resus-
pension of microspheres in a fresh PBS containing lysozyme.
Samples were assayed for CrmA concentration using ELISA
kits (PeproTech, USA) according to the manufacturer’s
protocols.
Chondrocytes isolation and culture conditions
Seven-day-old rats were obtained from the Experimental
Animal Center of Wuhan University, China, and were
fed under standard conditions (temperature:21 ± 1°C;
humidity:55–60%) with food and water continuously
available. The care and use of animals followed the recom-
mendations and guidelines of the National Institutes of
Health and were approved by the Wuhan University Animal
Care and Use Committee.
The cartilage tissues were harvested under sterile con-
ditions from the knees of seven-day-old rats. Then, the
cartilage tissues were cut into small pieces (<1 mm3)
and digested with 0.2% trypsin and 0.2% type II collage-
nase for 30 min and 2 hours respectively. After washing
twice with DMEM, isolated chondrocytes were sus-
pended in DMEM/F12 medium supplemented with 10%
fetal bovine serum (FBS) and 1% antibiotics at 37°C with
5% CO2. Cell viability was determined using cell viability
analyzer (viability > 90%). Primary cells were maintained
in monolayer culture throughout the study. After the
cells reached confluence, the medium was changed to
DMEM/F12 with 0.5% FBS and antibiotics for 6 hours.
Then IL-1β (10 ng/ml) was added to the culture medium
without rinse for a further 48 hours. The blank group
was cultured in DMEM/F12 with 10% FBS without
IL-1β, while the control group was only treated with
IL-1β. Chondrocytes were divided into five groups
cultured in DMEM/F12 containing 10%FBS without
antibiotics and incubated for a period of 4 h: A. blank
group, B. controls, C. chondrocytes cultured with CS
microspheres, D. chondrocytes cultured with HA-CS
microspheres, E. chondrocytes cultured with CS-CrmA
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CrmA microspheres. There were 5 samples in each
group and each experiment was repeated 5 times.
Determination of cell viability and GAG synthesis
After 72 hours of co-culture, the microspheres solution
was discarded, and the chondrocytes were removed to a
fresh media. After standardizing cell samples to one mil-
lion in different groups using a cell counter, 0.5 mg/ml
3-(4,5-Dimethylthiazol-2-yl)-2,5-dippphenyltetrazolium
bromide (MTT) was added to chondrocytes incubated
at 37°C with 5% CO2 for 4 h. The resulting formation
was dissolved in dimethylsulphoxide and absorbance
was measured at 570 nm with a microplate reader.
The GAG content in cell supernatants was assessed
using Blyscan assay kit (Biocolor, UK), and the chondro-
cytes were normalized to one million cells in each group.
Briefly, cell supernatants were digested enzymatically using
proteinase K. Following digestion, a desired amount of
supernatant was reacted with Blyscan dye for 30 min.
GAG-dye precipitate was obtained by centrifugation and
the resulting formation was dissolved in 1 ml dissociation
reagent and incubated for 10 minutes. Finally, samples
were transferred to a 96-well-plate and absorbance at
656 nm was measured on the spectrophotometer. A stand-
ard curve was derived from mixed-isomer shark chondro-
itin sulfate, and the GAG content was calculated.
Western blot for type II collagen, Aggrecan, type I
collagen and IL-1β
Proteins were extracted from harvested chondrocytes.
Protein concentrations were determined using a BCA
Protein Assay Kit. After adjusting to equal amounts
(50 ul protein per lane) of proteins, they were separated
by sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
under reducing conditions and then transferred onto
polyvinylidene difluoride membranes. Membranes were
blocked in phosphate buffered saline (PBS), pH 7.4,
containing 5% nonfat dry milk, and incubated with
anti-IL-1β, -type II collagen, Aggrecan, and -type I collagen,
respectively. Then incubated with horseradish peroxidase-
conjugated secondary antibodies (goat anti-rabbit IgG),
followed with visualization by the enhanced chemilu-
minescence kit.
Statistical analysis
SPSS 20.0 software was applied for data analysis. Data
were presented as the means ± S.D. of five separate experi-
ments. Each experimental condition was represented by
triplicate wells, with replicates from each culture averaged
and used as one value for analysis. Significant differences
among the mean values of multiple groups were evaluated
by one-way analysis of variance and Student-Newman-
Keuls q-test. P < 0.05 was considered as being significant.Results
Characterization of microspheres
The HA-CS-CrmA microspheres, fabricated using the
emulsification method in the presence of sTPP, were
spherical in shape, and the surfaces were smooth. Figure 1
showed the morphology of the microspheres. SEM showed
the microspheres were spherical and all the resulting micro-
spheres ranged in size from 8 μm to 15 μm (Figure 1.1).
The surfaces of these microspheres appeared to be loose
and porous, and the internal structure seemed cellular
(Figure 1.2). Regarding the variation in composition
and structure, it could be seen that both formulations
in the presence and absence of HA presented a gradual
increment in the size and morphology. There was a
slight increase in microsphere size in the presence of
HA (Figure 1.3, Figure 1.4). It was evident that the sur-
face of the microspheres with HA was more porous.
In vitro release profiles
The release kinetics of CrmA from different micro-
spheres was quite different, depicted in Figure 2. In the
HA-CS-CrmA group, the release rate of CrmA protein
was released lower than CS-CrmA group. The release
kinetics was monitored to 12 days, with the final release
of approximately 75% of CrmA within 10 d. Otherwise,
the CrmA from CS-CrmA microspheres was released in
a faster continuous manner, with a final release of ap-
proximately 84% in the same period. This indicated that
release kinetics of proteins from the microspheres was
influenced by structure of the microspheres. HA, carrying
high negative charges which allows the electrostatic inter-
action with protonated chitosan in an aqueous acidic solu-
tion, may result in slow drug release.
Assay of cell survival rate
The viability of chondrocytes cultured treatment groups
was evaluated by measuring their metabolic activity via
the MTT assay. Figure 3 displayed the percentage of
cell’s viability upon their different treatment. There were
three features that were worth mentioning. First, the
HA-CS-CrmA group presented a highest viability of 88%
compared to other control groups. Second, the fact that
HA microspheres group (80.5%) produced no statisti-
cally significant difference than the CS microspheres
group (81%). Further more, the HA-CS-CrmA group
presented a higher viability compared to the CS-CrmA
group yielding a percentage of 84.5%, which indicates
that CrmA played a crucial role in interaction with
chondrocytes.
GAG contents in cell supernatants
Total GAG quantity was tested to determine which sam-
ple group accumulated GAG with greater efficiency, and
it was shown in Figure 4. Results showed that all the
Figure 1 Characterization of microspheres. The image showed the characterization of microspheres detected by SEM. 1. Various size of
microspheres distributed uniformly. 2. The image of the surfaces and internal of these microspheres. 3.4 There is a slight increase in microsphere
size in the presence of HA (Figure 1.3, Figure 1.4).
Figure 2 The release kinetics of HA-CS-CrmA and CS-CrmA
microspheres. In the HA-CS-CrmA group, the release rate of
CrmA protein was released lower than CS-CrmA group with the
final release of approximately 84% of CrmA. The CrmA from CS-CrmA
microspheres was released in a faster continuous manner, with a final
release of approximately 75% in the same period. Statistical results
represented the mean ± S.D. of five separate experiments.﹟P < 0.05
VS. blank group;﹡P < 0.05 VS. Control group.
Figure 3 Viability of chondrocytes in different groups. The HA-
CS-CrmA group presents a highest viability of 88% compared to
other control groups. The HA microspheres group (80.5%) produces
no statistically significant difference than the CS microspheres group
(81%). The statistical results represented the mean ± S.D. of five
separate experiments. ﹟P < 0.05 VS. blank group; ﹡P < 0.05 VS.
Control group.
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Figure 4 Total GAG accumulated produced by chondrocytes
culture treatment group. All the treated groups demonstrated an
increase in GAG production compared with the IL-1β treated group.
And the HA-CS-CrmA group demonstrated significantly greater GAG
accumulation as compared to the control group. The statistical
results represented the mean ± S.D. of five separate experiments.
All data have been normalized to the blank group. ﹟P < 0.05 VS.
Blank group; ﹡P < 0.05 VS. Control group
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duction compared with the IL-1β treated group. And,
the HA-CS-CrmA group demonstrated significantly greater
GAG accumulation as compared to the control group
(p < 0.05). However, no statistically significant differ-
ence in GAG content was observed between the HA
microspheres treated group and the CS microspheres
treated group (p > 0.05).
Western blot for type II collagen, Aggrecan, collagen I
and IL-1β
As can be seen in Figure 5, type II collagen and aggrecan
expression by chondrocyte, which had been significantly
reduced by IL-1β exposure, was substantially restored by
HA-CS-CrmA microspheres. However, collagen I andFigure 5 Western blot analyses for type II collagen, aggrecan I,
collagen and IL-1beta. Type II collagen and aggrecan expression
was substantially restored by HA-CS-CrmA microspheres. However,
collagen I and IL-1β were decreased in HA-CS-CrmA group and
CS- CrmA group compared with the OA group.IL-1β decreased in HA-CS-CrmA group and CS- CrmA
group compared with the OA group. The results indi-
cated that the chondrocyte changed to normalization
when treated with microspheres, especially in the pres-
ence of CrmA.
Discussion
This study investigated that the feasibility of the novel
microspheres containing CrmA as a drug release system
to effectively interact with chondrocytes, produce thera-
peutic levels of ligand, ameliorate the dedifferentiation
of chondrocytes. Our results demonstrated that cell via-
bility, and ECM production such as GAGs and pheno-
type of the chondrocytes cultured with microspheres
evolved normalization compared with OA group. Based
on previous reports and our results, we reasonably de-
duce that the control-released CrmA from hyaluronic
acid-chitosan microspheres has a great potential as a
new way to protect chondrocyte in the process of OA.
In our study, one of the main factors affecting our
results was the microsphere structure. Comparing the
CS-CrmA group with HA-CS-CrmA group, it was not-
able that HA conjugation could enhance the ability of
the microspheres to interact with the chondrocytes
and to controlled-released drug. Collagen II, GAG and
aggrecan seemed more prominent in HA-CS-CrmA
microspheres. Moreover, collagen I and IL-1β downregu-
lation had previously been shown in chondrocytes treated
with HA-CS-CrmA microspheres. It has been reported
that HA treatment may prevent the IL-1β-induced down-
regulation of collagen II and proteoglycan in OA chondro-
cytes by blocking collagenases, so as to decelerate the
progression of OA [16]. Meanwhile, the control-released
action was demonstrated to last much longer in the pres-
ence of HA. More importantly, the efficiency of this re-
lease manner was improved by 12%. This may have been
due to the high negative charges and the very highly swol-
len gel-like characteristic of HA [17]. HA may promote
controlled-release by loosening the CS-protein bindingTable 1 The protein expressions of collagenII, Aggrecan,
collagenI and IL-1β
Group CollagenII Aggrecan CollagenI IL-1β
A 1.14 ± 0.07 1.26 ± 0.12 0.12 ± 0.03 0.30 ± 0.04
B 0.55 ± 0.12# 0.50 ± 0.06# 0.51 ± 0.10# 0.67 ± 0.02#
C 0.76 ± 0.03 0.75 ± 0.03 0.48 ± 0.04 0.59 ± 0.10
D 0.78 ± 0.08 0.76 ± 0.13 0.44 ± 0.06 0.57 ± 0.07
E 0.92 ± 0.05* 0.89 ± 0.08* 0.36 ± 0.08* 0.49 ± 0.11*
F 0.97 ± 0.04* 1.02 ± 0.05* 0.32 ± 0.11* 0.34 ± 0.06*
The statistical results represented the mean ± S.D. of five separate experiment.
Type II collagen and aggrecan expression was substantially restored in
HA-CS-CrmA group. However, collagen I and IL-1β were reduced in HA-CS-CrmA
group and CS- CrmA group compared with the OA group.
﹟P < 0.05 VS. blank group; ﹡P < 0.05 VS. control group.
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which can mediate the early stage of cell-substrate inter-
action [19]. Furthermore, CD44 is known as a cell surface
receptor for HA internalization and turnover [20,21].
CD44 is a transmembrane glycoprotein expressed in a var-
iety of cell types in connective tissues and a major cell sur-
face protein in chondrocytes, and is highly expressed in
inflammatory conditions [22]. This has been postulated to
have a function as the principal receptor for HA. Anti-
CD44 treatment using IM7 antibody has been reported to
activate some intracellular signaling pathways that block
the action of IL-1β [23]. Therefore, the application of HA
as a component of the microspheres might be a reason-
able approach for enhancing the interaction with chon-
drocytes in OA. Simultaneously, the presence of HA
could allow HA combining with CS through electrostatic
interaction [24]. It was observed that the size of the mi-
crospheres was strongly influenced when HA was in-
cluded in the microspheres.
GAG is a kind of polysaccharide, which together with
collagen type II forms the main components of the car-
tilage matrix. Secretion of GAGs by in vitro cultured
chondrocytes can be regarded as a sign that the chon-
drocytes phenotype is maintained [25]. TypeIIcollagen
and aggrecan could maintain the chondrocyte pheno-
type. This study demonstrated that microspheres were
able to prevent the IL-1β–induced breakdown of type II
collagen and proteoglycan in OA cartilage by decreasing
the secretion of IL-1β, leading to the deceleration of OA
progression. According to figures of Figure 3, 5 and
Table 1, we could deduce that cell viability correlated
very well with these chondrogenic markers. As shown in
Table 1, the expression of IL-1β and collagen I decreased,
while GAG, collagen type II, aggrecan production signifi-
cantly increased in HA-CS-CrmA group and CS-CrmA
group, but not signally in HA-CS group and CS group.
These data indicated that CrmA played a key role in the
microspheres in preventing the chondrocyte dedifferenti-
ation. CrmA is the natural inhibitor of ICE (caspase-1),
whose amino-acid sequence is similar to Acetyl-Asp-
Glu-Val-Asp-aldehyde (Ac-YVAD-CHO), a caspase-1-
specific inhibitor [26]. Caspase-1 has great specificity
for cleaving pro-IL-1β, thus decreasing the secretion of
IL-1β [27,28]. The suppression of inflammatory cyto-
kines activity within the joint might be one important
mechanism of the clinical action of the microspheres
in the treatment of OA. Since CrmA has not been
studied widely in the field of OA, it shows the advan-
tages in the application of protection of the chondro-
cyte in OA.
For the successful interaction with OA chondrocytes,
we prepared the HA-CS microspheres containing CrmA.
It was revealed that the sustained release of CrmA from
HA-CS microspheres could attenuate the degenerationof articular cartilage by maintaining the phenotype of
chondrocyte during culture expansion. The data derived
from this study suggest great promise to utilize HA-CS
microsphere as CrmA carriers for protection of the
chondrocyte in the process of OA.
Conclusions
In conclusion, our previous study has demonstrated that
HA could suppress chondrocyte apoptosis in IL-1β-
induced osteoarthritis model in a dose-dependent way.
In this study, for the first time, we found that the release
kinetics of CrmA were characterized by an initial burst
release, and the production of GAG and the expression
of type II collagen, aggrecan significantly increased com-
pared with the control group, while the expression of
collagen I and IL-1β decreased. These results indicated
that CrmA could attenuate the degeneration of articular
cartilage by maintaining the phenotype of chondrocytes
during culture expansion. The suppression of inflammatory
cytokines activity within the joint might be one important
mechanism of the clinical action of the microspheres in the
treatment of OA.
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